🍽️ bumetanide,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Diuretic Effect: Bumetanide belongs to the loop diuretic class of medications, which work by inhibiting the reabsorption of sodium and chloride in the kidneys, leading to increased urine production and elimination of excess fluid from the body. This helps reduce fluid buildup in tissues and organs, relieving symptoms of edema and reducing the workload on the heart.

  2. Congestive Heart Failure: Bumetanide is commonly prescribed to manage fluid overload in individuals with congestive heart failure (CHF), a condition characterized by impaired heart function and fluid retention. By promoting diuresis, bumetanide helps alleviate symptoms such as shortness of breath, swelling (edema), and fatigue associated with CHF.

  3. Hypertension: In some cases, bumetanide may be used as an adjunct therapy for the treatment of hypertension (high blood pressure), particularly when fluid retention contributes to elevated blood pressure levels. By reducing fluid volume, bumetanide can help lower blood pressure and improve cardiovascular function.

  4. Liver Cirrhosis: Bumetanide may be prescribed to manage ascites, a common complication of liver cirrhosis characterized by abdominal fluid accumulation. By increasing urine output, bumetanide helps alleviate ascites and associated symptoms such as abdominal distension and discomfort.

  5. Renal Disorders: Bumetanide is sometimes used to manage edema associated with renal disorders, including nephrotic syndrome and chronic kidney disease. By promoting diuresis, bumetanide helps reduce fluid retention and improve kidney function in these conditions.

  6. Potassium and Electrolyte Imbalance: Bumetanide can cause electrolyte imbalances, particularly hypokalemia (low potassium levels), as it increases the excretion of sodium and potassium in the urine. Healthcare providers may monitor electrolyte levels regularly and prescribe potassium supplements or potassium-sparing diuretics to prevent or correct electrolyte disturbances.

  7. Dehydration: Excessive diuresis induced by bumetanide can lead to dehydration, especially in vulnerable populations such as the elderly or individuals with preexisting dehydration risk factors. Patients are advised to maintain adequate fluid intake while taking bumetanide to prevent dehydration.

  8. Ototoxicity: Rarely, bumetanide may cause ototoxicity, characterized by reversible or irreversible hearing loss or tinnitus (ringing in the ears). Patients experiencing symptoms of ototoxicity should discontinue bumetanide and seek medical evaluation.

  9. Drug Interactions: Bumetanide may interact with other medications, including other diuretics, antihypertensive agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), potentially leading to additive effects on blood pressure, electrolyte balance, and kidney function. Healthcare providers should review patients' medication regimens to minimize the risk of drug interactions.

  10. Pregnancy and Lactation: Bumetanide should be used with caution during pregnancy and breastfeeding, as its safety profile in these populations is not well-established. Healthcare providers may weigh the potential benefits against the risks when prescribing bumetanide to pregnant or breastfeeding individuals.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of bumetanide,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by bumetanide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Ruminococcus genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Bifidobacterium genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bilophila wadsworthia species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of bumetanide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
Acne 0 0
ADHD 0.6 0.6
Allergic Rhinitis (Hay Fever) 0.1 0 0
Allergies 0.3 0.6 -1
Allergy to milk products 0.4 0 0
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 0.6 1.1 -0.83
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0 0.3 0
Ankylosing spondylitis 0.3 0.3 0
Anorexia Nervosa 0.6 -0.6
Antiphospholipid syndrome (APS) 0.1 0 0
Asthma 0.1 0.1 0
Atherosclerosis 0.3 0 0
Atrial fibrillation 0.7 0.1 6
Autism 0.8 0.9 -0.13
Barrett esophagus cancer 0.1 -0.1
Bipolar Disorder 0.4 0.3 0.33
Brain Trauma 0 0.1 0
Carcinoma 0.6 0.5 0.2
Celiac Disease 0.1 0.6 -5
Cerebral Palsy 0.1 0.5 -4
Chronic Fatigue Syndrome 0.9 0.5 0.8
Chronic Kidney Disease 0.2 0.2 0
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.4 0.4
Chronic Urticaria (Hives) 0.1 0.1
Coagulation / Micro clot triggering bacteria 0.1 0.5 -4
Colorectal Cancer 0.5 0.1 4
Constipation 0.1 0.2 -1
Coronary artery disease 0.4 0.2 1
COVID-19 1.2 2.2 -0.83
Crohn's Disease 0.8 0.7 0.14
cystic fibrosis 0.1 -0.1
deep vein thrombosis 0.4 -0.4
Depression 1.3 1.1 0.18
Dermatomyositis 0.1 0 0
Eczema 0.3 -0.3
Endometriosis 0.3 0.3 0
Epilepsy 0.3 0.2 0.5
Fibromyalgia 0.2 0.3 -0.5
Functional constipation / chronic idiopathic constipation 0.4 0.3 0.33
gallstone disease (gsd) 0.5 0 0
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0 0.4 0
Generalized anxiety disorder 0.2 0.1 1
giant cell arteritis 0 0
Glioblastoma 0.1 -0.1
Graves' disease 0.1 0.2 -1
Halitosis 0.1 0.1 0
Hashimoto's thyroiditis 0.4 0.1 3
Hidradenitis Suppurativa 0.1 0.1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0.3 -0.5
hypercholesterolemia (High Cholesterol) 0 0
hyperglycemia 0.2 -0.2
Hyperlipidemia (High Blood Fats) 0 0
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 0.4 0.4 0
Hypothyroidism 0.2 -0.2
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.3 -0.3
Inflammatory Bowel Disease 0.3 1.4 -3.67
Insomnia 0.3 0.1 2
Intelligence 0.2 0.2
Intracranial aneurysms 0.5 0.5
Irritable Bowel Syndrome 0.4 0.3 0.33
Liver Cirrhosis 0.7 0.5 0.4
Long COVID 0.4 1.6 -3
Lung Cancer 0.4 -0.4
ME/CFS with IBS 0.1 0.4 -3
ME/CFS without IBS 0.2 0.1 1
Menopause 0 0
Metabolic Syndrome 0.7 0.9 -0.29
Mood Disorders 1.7 1.1 0.55
multiple chemical sensitivity [MCS] 0.3 0.2 0.5
Multiple Sclerosis 0.9 0.7 0.29
Multiple system atrophy (MSA) 0.1 0.5 -4
Neuropathy (all types) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.3 1.1 -2.67
NonCeliac Gluten Sensitivity 0 0
Obesity 0.8 0.9 -0.13
obsessive-compulsive disorder 1.2 0.5 1.4
Osteoarthritis 0.2 0.3 -0.5
Osteoporosis 0.4 0.2 1
pancreatic cancer 0.1 0.1
Parkinson's Disease 0.1 0.6 -5
Polycystic ovary syndrome 0.6 0.6 0
Postural orthostatic tachycardia syndrome 0 0 0
Premenstrual dysphoric disorder 0.2 0.2
primary biliary cholangitis 0.2 -0.2
Psoriasis 0.6 0.1 5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.6 0.1 5
Rosacea 0.5 0 0
Schizophrenia 0.8 0.5 0.6
scoliosis 0.3 -0.3
Sjögren syndrome 0.2 0.6 -2
Sleep Apnea 0.5 0.2 1.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1
Stress / posttraumatic stress disorder 0.1 0.1 0
Systemic Lupus Erythematosus 0.3 0.5 -0.67
Tic Disorder 0.3 0 0
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 0.6 0.2 2
Type 2 Diabetes 0.6 0.9 -0.5
Ulcerative colitis 0.5 0.4 0.25
Unhealthy Ageing 0.4 0.2 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.